Медико-биологический
информационный портал
для специалистов
 
БИОМЕДИЦИНСКИЙ ЖУРНАЛ Medline.ru

СОДЕРЖАНИЕ ЖУРНАЛА:
Физико-химическая биология

Клиническая медицина

Профилактическая медицина

Медико-биологические науки


АРХИВ:

Фундаментальные исследования

Организация здравохраниения

История медицины и биологии



Последние публикации

Поиск публикаций

Articles

Архив :  2000 г.  2001 г.  2002 г. 
               2003 г.  2004 г.  2005 г. 
               2006 г.  2007 г.  2008 г. 
               2009 г.  2010 г.  2011 г. 
               2012 г.  2013 г.  2014 г. 
               2015 г.  2016 г.  2017 г. 
               2018 г.  2019 г. 

Редакционная информация:
        Опубликовать статью
        Наша статистика


 РЕДАКЦИЯ:
Главный редактор

Заместители главного редактора

Члены редколлегии
Специализированные редколлегии


 УЧРЕДИТЕЛИ:
Федеральное государственное бюджетное учреждение науки
"Институт токсикологии Федерального медико-биологического агентства"
(ФГБУН ИТ ФМБА России)

Институт теоретической и экспериментальной биофизики Российской академии наук.

ООО "ИЦ КОМКОН".




Адрес редакции и реквизиты

199406, Санкт-Петербург, ул.Гаванская, д. 49, корп.2

ISSN 1999-6314

Российская поисковая система
Искать: 


«
Vol. 15, Art. 56 (pp. 703-717)    |    2014       
»

The quality of life of anemic patients with lymphoproliferative disorders treated with red blood cell transfusions and erythropoiesis-stimulating agents
Romanenko N.A.1, Bessmeltsev S.S.1, Potikhonova N.A.1, Romanenko A.E.2, Zenina M.N.1, Abdulkadyrov K.M.1

1Russian Research Institute of Hematology and Transfusiology, Russian Federal of Medical-biological Agency, Saint-Petersburg, 191024, 2nd Sovietskaya str., 16
2Children Hospital of St. Olga, Saint-Petersburg, 194156, str. Zemledelcheskaya, 2



Brief summary

Aims. To assess alteration of quality of life (QoL) in anemic patients with lymphoproliferative disorders (LPD) treated with Red blood cells transfusions (RBCsT) and Erythropoiesis-stimulating agents (ESA). Patients and Methods. There were included 131 anemic patients with LPD (multiple myeloma, low-grade non-Hodgkin\'s lymphoma, chronic lymphocytic leukemia). Median age of patients was 67 years (range 24-85). All persons were divided into two groups: 1st group included patients (n=54) treated with RBCsT, 2nd (n=77) – treated with ESA. Posetive response for ESA considered as achievement of hemoglobine concentration 120 g/L or increase Hb ≥ 20 g/L. QoL was studied with Functional Assessment of Cancer Therapy Anemia subscale (FACT-An) and Fatigue subscale (FACT-F). Results. In the 1st group of patients treated with RBCsT (in average 3.7±0.3 Units) concentration of Hb increased from 70.0±1.6 g/L to 93.1±1.2 g/L. Statistically significant improvement of their QoL was found in FACT-An subscale – from 41.1±2.0 (95% Cl=37.1-45.0) to 34.2±2.1 (95% Cl=30.0-38.3) points (p<0.001; n=54). Improvement of QoL was also found in FACT-F subscale – from 30.2±1.4 (95% Cl=27.8-32.9) to 23.2±1.5 (95% Cl=19.8-26.9) points (p<0.0001; n=54). In the 2nd group positive response for ESA-therapy was found in 52 (67.5%) out of 77 patients: 39 (50.6%) patients achieved the Hb concentration 120 g/L and 13 (16.9%) ones increased Hb more than 20 g/L. The patients with positive response increased the Hb concentration significantly from 88.4±1.4 g/L to 123.1±2.4 g/L (p<0.0001; n=52). We found out improvement of QoL in both subscale: in FACT-An – from 34.5±1.7 (95% Cl=31.1-37.9) to 30.1±1.6 (95% Cl=26.9-33.2) points (p<0.001; n=52) and in FACT-F – from 22.8±1.3 (95% Cl=20.3-25.4) to 19.7±1.2 (95% Cl=17.3-22.1) points (p=0.013; n=52). Conclusions. Both RBCsT and ESA-therapy are able to increase Hb concentration considerably and improve QoL. However the RBCsT patients had more severe anemia and over a period of its correction the RBCsT patients’s planned level of Hb was less than ESA-patietnts’s one therefore their final QoL was less. So using the ESA-therapy can increase higher Hb concentration and improve QoL more than RBCsT. It’s indicating importance of ESA-therapy not as alternative RBCsT method of anemia’s correction but also as a way to prevent decreasing of the Hb induced by toxic effect of chemotherapy and as a method of anemia treatment with which a normal Hb level can be achieved.


Key words

lymphoproliferative disorders, erythropoiesis-stimulating agents, anemia, hemoglobin, red blood cell, red blood cell transfusions, hematologic, quality of life, subscale FACT-An, FACT-F





(The article in PDF format. For preview need Adobe Acrobat Reader)



Open article in new window

Reference list

1. Bessmelcev S.S., Romanenko N.A., Abdylkadirov K.M. Sovremennie podhodi k lecheniu anemii y bolnih s onkogematologicheskimi zabolevaniyami// Sovremennaya onkologiya. – 2010. – T. 12, №1. – S. 70-75.


2. Moullet I., Salles G., Ketterer N. et al. Frequency and significance of anemia in non-Hodgkin’s lymphoma patients// Ann. Oncol. – 1998. – Vol. 9. – P. 1109-1115.


3. Zupanić-Krmek D.,  Lang N.,  Jurcić D. et al. Analysis of the influence of various factors on anemia in patients with lymphoid malignancies// Acta Clin. Croat. – 2011. – Vol. 50, №4. – P. 495-500.


4. Truong P.T., Parhar T., Hart J. et al. Population-based analysis of the frequency of anemia and its management before and during chemotherapy in patients with malignant lymphoma// Am. J. Clin. Oncol. – 2010. – Vol. 33, №5. – P. 465-468.


5. Romanenko N.A., Abdylkadirov K.M. Patogeneticheskaya korrekciya anemii eritropoezstimyliryushimi preparatami y bolnih limfoproliferativnimi zabolevaniyami// Onkogematologiya.- 2011.- №3.- S. 39-49.


6. Gricaev S.V., Davaasambyy B., Romanenko N.A., Abdylkadirov K.M. Otbor bolnih dlya terapii helatorami jeleza// Klin. Onkogematologiya. – 2013. – T.6, №2. – S. 204-209.


7. Khorana A.A., Francis C.W., Blumberg N. et al. Blood Transfusions, Thrombosis, and Mortality in Hospitalized Patients With Cancer// Arch. Intern. Med. – 2008. – Vol. 168, №21. – P. 2377-2381.


8. Leitch H.A., Vickars L.M. Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?// Hematology Am. Soc. Hematol. Educ. Program. – 2009. – P. 664-672.


9. Romanenko N.A., Bessmelcev S.S., Berkos M.V., Rozanova O.E., Abdylkadirov K.M. Prognosticheskaya znachimost ryada laboratornih pokazatelei krovi pri ispolzovanii preparatov, stimyliryushih eritropoez y bolnih limfoproliferativnimi zabolevaniyami s anemiei// Ter. Arhiv. – 2013. – T.85, №8. – S.81-86.


10. EORTC guidelines for the use of erythropoietic proteins in anemic patients with cancer: 2006 update/ C. Bokemeyer, M.S. Aapro, A. Courdi et al.// Eur. J. Cancer. – 2007. – Vol. 43. – P. 258-270.


11. Cazzola M., Beguin Y., Kloczko J. et al.Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin Production// Br. J. Haematol. – 2003. – Vol. 122, №3. – P. 386-393.


12. Haioun C., Salar A., Pettengell R. et al.Anemia and erythropoiesis-stimulating agent administration in patients with non-Hodgkin lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone with/ without rituximab chemotherapy: results from an observational study// Leukemia & Lymphoma. – 2011. – Vol. 52. – P. 796-803.


13. Romanenko N., Kostroma I., Abdulkadyrov K. Comparative study the efficacy of different erythropoiesis-stimulative agents in anemic patients with lymphoproliferative disorders// Haematologica - The Hematology journal. – 2013. – Vol. 98, Suppl. 1. – S 648.


14. Campos M.P.O., Hassan B.J., Riechelmann R., Del Giglio A. Cancer-related fatigue: a practical review// Annals of Oncology. – 2011. – Vol.22, N6. – P. 1273–1279.


15. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue// Semin Hematol. – 1997. –Vol. 34 (3 Suppl 2) . – P. 13-19.


16. Christodoulou C., Dafni U., Aravantinos G. et al. Effects of Epoetin-α on Quality of Life of Cancer Patients with Solid Tumors Receiving Chemotherapy// Anticancer Research. – 2009. –Vol. 29. – P. 693-702.


17. Romanenko N.A. Bessmelcev S.S., Karmackaya I.I., Potihonova N.A., Abdylkadirov K.M. Effektivnost eritropoezstimyliryushih preparatov i ih vliyanie na kachestvo jizni bolnih s anemiei pri limfoproliferativnih zabolevaniyah// Kaz.med.jyrnal. – 2013. – T. XCIV, №4. – S. 468-473.


18. Yellen S.B., Cella D.F., Webster K. et al. Measuring fatigue, and other anemia related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system// J Pain Symptom Manage.–1997.– Vol.13.– P. 63-74.


19. Yoshimura A., Kobayashi K., Fumimoto H. et al. Cross-Cultural Validation of Japanese Functional Assessment of Cancer-Therapy Anemia (FACT-An)// J Nippon Med Sch.– 2004.–Vol. 71,N5.– P. 314-322.


20. Instrykciya po primeneniu komponentov krovi (Ytverjdennaya Prikazom Minzdrava ot 25 noyabrya 2002 goda RF №363 «Ob ytverjdenii Instrykcii po primeneniu komponentov krovi»)// [Elektronnii resyrs]// http://www.zdrav.ru/library/regulations/detail.php?ID=26150.


21. Pravila klinicheskogo ispolzovaniya donorskoi krovi i (ili) ee komponentov/ Prikaz ot 2 aprelya 3013 g. №183n «Ob ytverjdenii pravil klinicheskogo ispolzovaniya donorskoi krovi i (ili) ee komponentov» [Elektronnii resyrs]// http://www.transfusion.ru/2013/08-29-1.pdf.


22. Rizzo J.D., Brouwers M., Hurley P. et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer// Blood. – 2010. – 116, N20 . – P. 4045-4059.


23. Vadhan-Raj S., Zhou X., Sizer K. et al. Impact of safety concerns and regulatory changes on the usage of erythropoiesis-stimulating agents and RBC// The Oncologist.– 2010.– Vol. 15.–P.1359-1369.



Свидетельство о регистрации сетевого электронного научного издания N 077 от 29.11.2006
Журнал основан 16 ноября 2000г.
Выдано Министерством РФ по делам печати, телерадиовещания и средств массовых коммуникаций
(c) Перепечатка материалов сайта Medline.Ru возможна только с письменного разрешения редакции

Размещение рекламы

Rambler's Top100